Managed care pharmacists can help save money

Program identified millions in health care savings when pharmacists help members optimize drug therapy

Prime and a Blue Plan client together developed a program to helped Medicare and commercial members with certain health conditions optimize their drug therapy. Pharmacists reviewed claims to identify high risk and high cost members. The pharmacists worked with care teams and conducted outreach. The Blue Plan verified a 10:1 ROI from the program.

Thinking Outside the Bottle: How A Clinical Pharmacist Team Adds Value and Saves Money in a Managed Care Plan (Spring 2017)

About Prime Therapeutics

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization serving health plans, employers and government programs. Prime is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management LLC, a Prime Therapeutics LLC Company, is a pioneer in specialty and medical drug management and a leader in serving public sector state government programs. Together Prime and Magellan Rx provide a wide range of clients with solutions that bridge the distance between medical and pharmacy management. For more information visit primetherapeutics.com and magellanrx.com or follow us on X (Twitter) at @Prime_PBM and @Magellan_Rx.

Related news

Perspectives

April 25, 2024

Drug Approvals Monthly Update: April 2024

This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals…

Perspectives

April 24, 2024

Prime/MRx resident wins AMCP Foundation Best Poster Award

Ai Quynh Nguyen, PharmD, was recently recognized for her research on opioid-prescribing patterns and outcomes

Perspectives

April 23, 2024

Expert Clinical Network Insights: April 2024

A look into our Expert Clinical Network (ECN) – part of Prime/MRx’s value-based approach to medical and pharmacy benefit management that offers access to more than 175 national and world-renowned key opinion leaders in multiple disease categories who provide expertise on challenging prior authorization case reviews, peer-to-peer discussions, drug policy development and formulary guidance

View all news